Company profile
Ryvu Therapeutics
Developing novel treatments at the forefront of oncology
- Industry
- Biotechnology
- Employees
- 218
- Headquarters
- Kraków, Małopolska
- Founded
- 2007
- LinkedIn followers
- 14,884
- Office locations
- 1
Ryvu Therapeutics company summary
Ryvu Therapeutics is a company in the Biotechnology industry, headquartered in Kraków, Małopolska, founded in 2007. On LinkedIn the company has around 218 employees and 14,884 followers. Its listed specialties include oncology, drug discovery, biotech, kinase inhibitor, cancer metabolism.
What technology does Ryvu Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. Ryvu’s most advanced programs are RVU120 - a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors, and SEL24 (MEN1703) - dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in Phase II clinical studies in acute myeloid leukemia. In its history, Ryvu Therapeutics has signed 11 partnering and licensing deals with global companies, among others Merck, Menarini Group, Galapagos, Exelixis, and BioNTech. The company was founded in 2007 and is headquartered in Krakow, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of sWIG80 index.
Specialties
Where is Ryvu Therapeutics located?
Ryvu Therapeutics lists 1 location.
Compare companies similar to Ryvu Therapeutics
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Ryvu Therapeutics ryvu.com | Biotechnology | 218 | 2007 | Kraków, Małopolska |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about Ryvu Therapeutics
What does Ryvu Therapeutics do?
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. Ryvu’s most advanced programs are RVU120 - a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors, and SEL24 (MEN1703) - dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in Phase II clinical studies in acute myeloid leukemia. In its history, Ryvu Therapeutics has signed 11 partnering and licensing deals with global companies, among others Merck, Menarini Group, Galapagos, Exelixis, and BioNTech. The company was founded in 2007 and is headquartered in Krakow, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of sWIG80 index.
How many employees does Ryvu Therapeutics have?
Ryvu Therapeutics has around 218 employees on LinkedIn.
Where is Ryvu Therapeutics headquartered?
Ryvu Therapeutics is headquartered in Kraków, Małopolska.
When was Ryvu Therapeutics founded?
Ryvu Therapeutics was founded in 2007.
Build a lead list from companies like Ryvu Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.